| EN
澳门PG电子游戏APP官方网站 has been continuously expanding its R&D investments. In 2021, its R&D investment was more than CNY 1.4 billion, accounting for 28.3% of the sales revenue.
With four R&D centers in Shanghai, Nanjing, Beijing and Boston, the company has established a whole-process R&D system integrating drug discovery, pre-clinical development, clinical trials, and drug registration, owns a R&D pipeline project of nearly 60 new drugs, and is conducting 22 clinical studies for registration of 19 potential innovative drugs.

Global R&D Center Layout

Boston R&D Center

Nanjing R&D Center

Shanghai R&D Center

R&D Pipeline

We have nearly 60 innovative product candidates in different stages of development, among which over 10 product candidates had obtained the IND approval or were at clinical stage.

MORE+

Massachusetts is home to 19% of the top pharmaceutical product pipelines in the United States and 9% globally. The state capital, Boston, in particular holds a dominating position in the global life sciences community.

澳门PG电子游戏APP官方网站’s Boston R&D Center focuses on the world's cutting-edge cell and gene therapies, and with its team of pioneering scientists, it remains dedicated to building a world-class R&D center. Utilizing the world's state-of-the-art technologies, we are rapidly building several cutting-edge technology platforms for cell and gene therapies and thereby making the Boston R&D Center a powerful pipeline driver for 澳门PG电子游戏APP官方网站 through the institute’s fast and efficient project promotion system.